SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver ...
Early initiation of diuretic therapy in patients with new onset cirrhotic ascites lowers 90-day mortality rate, according to a study in the American Journal of Gastroenterology. Researchers examined ...
IL-1β and IL-6 as predictors of ypN and early response to neoadjuvant chemotherapy in patients with locally advanced GC and GEJ cancer. This is an ASCO Meeting Abstract from the 2023 ASCO ...
Prognostic impact of hyponatremia in patients with pancreatic cancer: A nationwide analysis. Description of technique for endoscopic ultrasound-guided tissue acquisition in pancreatic cancer for ...
FORT LAUDERDALE, Fla., Dec. 31, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF), a nonprofit dedicated to raising awareness, funding research, and supporting stomach cancer ...
Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted orphan drug designation to Ocelot Bio’s OCE-205, a mixed vasopression 1a receptor ...
Research, headed by teams at Trinity College Dublin and University College Dublin, has uncovered how lipid-rich fluid in the abdomen, known as ascites, plays a central role in weakening the body’s ...
In this study, researchers aimed to determine whether ctDNA is detectable in other bodily fluids besides blood, and to characterize any ctDNA they were able to detect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback